NCT02279095 - An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 9, 2014

Primary Completion Date

September 20, 2022

Study Completion Date

September 20, 2022

Conditions

Fibrodysplasia Ossificans Progressiva

Interventions

DRUG

Palovarotene dose level 1

Palovarotene was taken orally once daily at approximately the same time each day.

DRUG

Palovarotene dose level 2

Palovarotene will be taken orally once daily at approximately the same time each day.

DRUG

Palovarotene dose level 3

Palovarotene will be taken orally once daily at approximately the same time each day.

DRUG

Palovarotene dose level 4

Palovarotene will be taken orally once daily at approximately the same time each day.

Trial Locations (8)

Royal North Shore Hospital, Saint Leonards

Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI), Woolloongabba

University of Pennsylvania, Center for FOP & Related Bone Disorders, Philadelphia

Mayo Clinic, Department of Medicine, Rochester

University of California San Francisco, Division of Endocrinology and Metabolism, San Francisco

Hospital Italiano de Buenos Aires, Department of Pediatrics, Buenos Aires

Hôpital Necker-Enfants Malades, Department of Genetics, Paris

The Royal National Orthopaedic Hospital, Brockley Hill, Stanmore